15 active not recruiting. 15 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 15 | Active not recruiting 15 |
| Phase 2 | 3 | Active not recruiting 3 |
Follow Lymphoma, Large B-Cell, Diffuse: new trials by email Literature Review of Lymphoma, Large B-Cell, Diffuse trials Research Report on Lymphoma, Large B-Cell, Diffuse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma SHR-A1912 Injection, Rituximab Injection, Gemcitabine Hydrochloride for Injection - Diffuse Large B-cell Lymphoma | Phase 3 | Active not recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 282 | 2025-04-24 | 2026-09-25 |
| A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Epcoritamab, Rituximab, Lenalidomide - Diffuse Large B-Cell Lymphoma | Phase 3 | Active not recruiting | Genmab | 379 | 2024-08-13 | 2026-04-08 |
| A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) Epcoritamab, Cyclophosphamide, Rituximab - Diffuse Large B-Cell Lymphoma | Phase 3 | Active not recruiting | Genmab | 900 | 2023-02-08 | 2026-09-11 |
| Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND) Tafasitamab, Lenalidomide - Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma | Phase 3 | Active not recruiting | Incyte Corporation | 82 | 2022-12-23 | 2026-10-22 |
| A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China Epcoritamab, Investigator's Choice Chemotherapy - Diffuse Large B-Cell Lymphoma | Phase 3 | Active not recruiting | Genmab | 72 | 2022-10-08 | 2026-05-05 |
| Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma Biospecimen Collection, Computed Tomography, Cyclophosphamide - Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 422 | 2021-05-20 | 2026-10-27 |
| Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients Tafasitamab, Lenalidomide, Rituximab - Diffuse Large B-cell Lymphoma | Phase 3 | Active not recruiting | Incyte Corporation | 899 | 2021-05-11 | 2026-04-01 |
| A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Obinutuzumab, Glofitamab, Rituxumab - Diffuse Large B-cell Lymphoma | Phase 3 | Active not recruiting | Hoffmann-La Roche | 270 | 2021-02-23 | 2026-10-02 |
| A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Epcoritamab, Investigator's Choice Chemotherapy - Diffuse Large B-cell Lymphoma | Phase 3 | Active not recruiting | Genmab | 483 | 2021-01-13 | 2026-05-22 |
| A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) acalabrutinib, placebo, Prednisone - Diffuse Large B-Cell Lymphoma | Phase 3 | Active not recruiting | Acerta Pharma BV | 611 | 2020-10-08 | 2026-10-13 |
| Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Loncastuximab Tesirine, Rituximab, Gemcitabine - Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 3 | Active not recruiting | ADC Therapeutics S.A. | 440 | 2020-09-16 | 2026-04-28 |
| A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy) - Relapsed/Refractory Diffuse Large B-cell Lymphoma | Phase 2 / Phase 3 | Active not recruiting | Karyopharm Therapeutics Inc | 501 | 2020-09-03 | 2026-10-02 |
| Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL Brentuximab vedotin, Rituximab, Lenalidomide - Diffuse Large B-cell Lymphoma | Phase 3 | Active not recruiting | Seagen, a wholly owned subsidiary of Pfizer | 240 | 2020-08-20 | 2026-10-21 |
| Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 363 | 2019-10-22 | 2026-10-26 |
| A Long-term Extension Study of PCI-32765 (Ibrutinib) Ibrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 539 | 2013-09-09 | 2026-10-01 |
Lymphoma (2) · Lymphoma, Non-Hodgkin (2) · Neoplasms (2) · Recurrence (2) · Bronchiolitis Obliterans Syndrome (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphatic Diseases (1) · Lymphoma, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Mantle-Cell (1) · Lymphoproliferative Disorders (1) · Waldenstrom Macroglobulinemia (1)
Hemic and Lymphatic Diseases (15) · Immune System Diseases (15) · Immunoproliferative Disorders (15) · Neoplasms by Histologic Type (15) · Lymphatic Diseases (14) · Lymphoma, B-Cell (14) · Lymphoproliferative Disorders (14) · Lymphoma (13) · Lymphoma, Non-Hodgkin (13) · Neoplasms (13) · Disease Attributes (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Blood Protein Disorders (1) · Bronchial Diseases (1)
Rituximab (10) · Cyclophosphamide (5) · Doxorubicin (5) · Gemcitabine (5) · Prednisone (5) · Vincristine (5) · Lenalidomide (4) · Oxaliplatin (4) · CT-P10 (2) · Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · deltacortene (2) · prednylidene (2) · tafasitamab (2) · Azacitidine (1)
Genmab (4) · Incyte Corporation (2) · National Cancer Institute (NCI) (2) · ADC Therapeutics S.A. (1) · Acerta Pharma BV (1) · Hoffmann-La Roche (1) · Janssen Research & Development, LLC (1) · Karyopharm Therapeutics Inc (1) · Seagen, a wholly owned subsidiary of Pfizer (1) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (1)
United States (12) · Poland (11) · China (9) · France (9) · Spain (9) · United Kingdom (9) · Australia (8) · Belgium (8) · Canada (8) · Czechia (8) · Israel (8) · Italy (8) · South Korea (8) · Taiwan (8) · Turkey (Türkiye) (8)
Elizabeth A Brem (1) · Jeremy S Abramson (1) · Oliver Manzke, MD (1)
PMID 34634256, PMID 34686472, PMID 34780623, PMID 37369099, PMID 39319495, PMID 39550172, PMID 39772655, PMID 40749164, PMID 40993016, PMID 42217458, PMID 42269085, PMID 42660130
2023 (4), 2019 (1), U10CA180821 (1), U10CA180888 (1)